U.S. markets open in 1 hour 18 minutes

Nanobiotix S.A. (NBTX)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
19.49-0.19 (-0.99%)
At close: 3:59PM EST

18.85 -0.64 (-3.28%)
Before hours: 8:00AM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close19.68
Open19.49
Bid17.65 x 2200
Ask19.38 x 800
Day's Range19.20 - 19.56
52 Week Range15.89 - 21.55
Volume4,529
Avg. Volume72,711
Market Cap660.658M
Beta (5Y Monthly)2.04
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Nanobiotix Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021
      Business Wire

      Nanobiotix Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021

      NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company"), a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment, today announced positive first results from the complete phase Ib part of a phase Ib/II study evaluating NBTXR3 (PEP503) activated by radiotherapy with concurrent chemotherapy. This study is sponsored and administered by PharmaEngine, Inc. in Taiwan pursuant to a License and Collaboration agreement with the Company. The data were presented at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI 2021).

    • Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering
      Business Wire

      Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering

      NANOBIOTIX (Paris:NANO) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy and increasing the proportion of patients that respond to immune checkpoint inhibitors, today announced its global development plan for 2021 and beyond.